For lung cancer patients who experience grade 3/4 toxicity from a PD-1 inhibitor necessitating cessation of therapy, but whose tumor has responded to the treatment, do you consider restarting PD-1 inhibitor therapy at the time when they progress again?

This is a highly challenging question that all of us face now with increasing frequency given the ever-widening utilization of checkpoint inhibitors. A decision as to resuming an anti-PD-1/PD-L1 agent in a patient who suffered a serious immune-mediated side effect clearly requires great judgment and...